TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis-Reference-Cited by-同舟云学术

TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis

Published:2020-06-19 Issue:25 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Rosikiewicz Wojciech¹²^ORCID,Chen Xiaowen¹^ORCID,Dominguez Pilar M.³^ORCID,Ghamlouch Hussein⁴^ORCID,Aoufouchi Said⁵^ORCID,Bernard Olivier A.⁴,Melnick Ari³^ORCID,Li Sheng¹⁶⁷⁸^ORCID

Affiliation:

1. The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

2. Center for Applied Bioinformatics, St. Jude Children’s Research Hospital, Memphis, TN, USA.

3. Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

4. INSERM U1170, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

5. CNRS UMR8200, équipe labelisée Ligue Nationale Contre le Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

6. The Jackson Laboratory Cancer Center, Bar Harbor, ME, USA.

7. Department of Genetics and Genome Sciences, University of Connecticut Health Center, Farmington, CT, USA.

8. Department of Computer Science and Engineering, University of Connecticut, Storrs, CT, USA.

Abstract

TET2 deficiency reprograms B cell epigenome linked to lymphomagenesis.

Funder

National Cancer Institute

National Institute of General Medical Sciences

Lymphoma Research Foundation

Samuel Waxman Cancer Research Foundation

Chemotherapy Foundation

Leukemia and Lymphoma Society

Follicular Lymphoma Consortium

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference82 articles.

1. Epigenetics of hematopoiesis and hematological malignancies

2. Germinal center‐derived lymphomas: The darkest side of humoral immunity

3. The many layers of epigenetic dysfunction in B-cell lymphomas

4. Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome

5. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic Alterations That Are the Backbone of Immune Evasion in T-cell Malignancies;Cureus;2024-01-04

2. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target;Clinical Lymphoma Myeloma and Leukemia;2023-08

3. Characterizing the Spectrum of Epigenetic Dysregulation Across Lymphoid Malignancies;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Future Prospects for Targeting the Epigenome in Lymphomas;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

5. The Role of Epigenetic Dysregulation in Lymphoma Biology;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15